CA-USERTESTING
31.3.2022 15:02:11 CEST | Business Wire | Press release
UserTesting (NYSE: USER), a leader in video-based human insight , today released the 2022 CX Industry Report that reveals a strong global demand for actionable human insight across every industry and every size organization as customers’ needs and expectations continue to evolve and grow. Accessing customer perspectives to stay relevant and competitive is now a requirement for business success.
When surveyed about their top priorities for the year, executives overwhelmingly reported that addressing market changes related to the pandemic was a top priority for them, jumping to 65 percent, a 35 percent increase over last year. One strong indication for how executives plan to address this priority is looking to customer experience to stay competitive and grow.
Although the survey found that executives and employees are enthusiastic about making customer empathy a part of their regular business processes, a lack of time, resources and organizational support continue to be key obstacles. Teams can’t meet the demand for human insight if their organizations aren’t structured to operationalize the strategy, and that’s where executives come into play. Organizations are relying on executive leadership to help address that last mile of the CX maturity journey.
The 2022 CX Industry Report revealed three key trends influencing the future of customer experience and human insight:
-
Human insight is in high demand
A better understanding of the customer has never been more important. Human insight plays a pivotal role in not only creating better customer experiences but helping organizations develop better products and services. The value of human insight is clear as the research revealed that having a dedicated team for UX and CX research increased by 39 percent since 2020. Despite this growth, UX and CX researchers reported that they don’t have the capacity to take on more work. Less than half (44 percent) say that they can keep up with the requests they get for research projects, which aligns with what other teams report as well. A lack of time, resources, and feedback platform were the key roadblocks for these teams when it comes to gaining human insight.
-
Improving CX maturity hasn’t translated into execution (yet)
Meeting the demand for human insight has been challenging but despite this, many organizations reported that they have been improving their CX maturity. Since first being asked in 2020 how mature their organizations were when it came to providing great CX, teams have consistently reported improvements year over year, with a 50 percent improvement between 2020 and 2022. However, the improvements in maturity don’t lead to fully executed CX strategies. Less than 50 percent of all marketers, designers, and product teams reported that they’re regularly getting feedback on key experiences they create.
-
CX is both a solution and a challenge for many executives
Executives recognize the value of human insight to create great customer experiences—seventy-eight percent of executives noted that CX is a top area of investment for them. However, expectations and reality are not yet aligned. It was found that 80 percent of executives say they have a strategy in place to improve customer experience, yet only 19 percent of respondents would describe their organization as “Visionary” when it comes to CX maturity. Although executives may think they have a strategy and investment plan in place to help them compete based on CX, their teams are reporting otherwise.
“It is encouraging that more executives see the value of including customer feedback in the decision making process, yet it’s equally disconcerting that companies are challenged with being able to truly operationalize their customer experience strategies,” said Janelle Estes, chief insights officer at UserTesting. “When organizations fail to listen to their customers and are unable to put themselves in their customers’ shoes, they risk missing out on opportunities to grow their business and strengthen their product and experiences.”
To access the full UserTesting 2022 CX Industry Report, click here .
Methodology and survey results
In this ninth annual Customer Experience Industry Survey, we asked over 5,100 professionals from around the world across a wide variety of industries how their organizations are approaching customer experience and conducting CX research.
About UserTesting
UserTesting (NYSE: USER) has fundamentally changed the way organizations get insights from customers with fast, opt-in feedback and experience capture technology. The UserTesting® Human Insight Platform taps into our global network of real people and generates video-based recorded experiences, so anyone in an organization can directly ask questions, hear what users say, see what they mean, and understand what it’s actually like to be a customer. Unlike approaches that track user behavior then try to infer what that behavior means, UserTesting reduces guesswork and brings customer experience data to life with human insight. UserTesting has more than 2,300 customers, including more than half of the world’s top 100 most valuable brands according to Forbes. UserTesting is headquartered in San Francisco, California. To learn more, visit www.usertesting.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005353/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 12:00:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission
KRM22 partners with Sigma AI to enhance market surveillance and risk intelligence capabilities15.6.2026 12:00:00 CEST | Press release
KRM22, the technology and software investment company focused on risk management solutions for capital markets, today announced a strategic partnership with Sigma AI, a leading provider of AI-driven financial insights, to integrate advanced news sentiment analytics into its risk management application suite. The integration marks a significant enhancement to KRM22’s capabilities, enabling clients to incorporate real-time market sentiment insights derived from global news sources directly into their risk frameworks. By leveraging Sigma AI’s proprietary natural language processing and machine learning models, KRM22 will help firms better identify emerging risks, anticipate market-moving events, and make more informed trading and compliance decisions. Advancing risk management through AI-driven sentiment analysis As part of the first phase of the collaboration, KRM22 will embed Sigma AI’s news sentiment engine within its application suite. This will provide users with actionable intellige
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release
The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
